Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study.

Risk assessment Transitional cell carcinoma Ureteroscopy Urologic neoplasms Urologic surgical procedures Urological diagnostic techniques

Journal

European urology focus
ISSN: 2405-4569
Titre abrégé: Eur Urol Focus
Pays: Netherlands
ID NLM: 101665661

Informations de publication

Date de publication:
03 2022
Historique:
received: 07 01 2021
revised: 23 02 2021
accepted: 14 03 2021
pubmed: 29 3 2021
medline: 9 6 2022
entrez: 28 3 2021
Statut: ppublish

Résumé

The European Association of Urology risk stratification dichotomizes patients with upper tract urothelial carcinoma (UTUC) into two risk categories. To evaluate the predictive value of a new classification to better risk stratify patients eligible for kidney-sparing surgery (KSS). This was a retrospective study including 1214 patients from 21 centers who underwent ureterorenoscopy (URS) with biopsy followed by radical nephroureterectomy (RNU) for nonmetastatic UTUC between 2000 and 2017. A multivariate logistic regression analysis identified predictors of muscle invasion (≥pT2) at RNU. The Youden index was used to identify cutoff points. A total of 811 patients (67%) were male and the median age was 71 yr (interquartile range 63-77). The presence of non-organ-confined disease on preoperative imaging (p < 0.0001), sessile tumor (p < 0.0001), hydronephrosis (p = 0.0003), high-grade cytology (p = 0.0043), or biopsy (p = 0.0174) and higher age at diagnosis (p = 0.029) were independently associated with ≥pT2 at RNU. Tumor size was significantly associated with ≥pT2 disease only in univariate analysis with a cutoff of 2 cm. Tumor size and all significant categorical variables defined the high-risk category. Tumor multifocality and a history of radical cystectomy help to dichotomize between low-risk and intermediate-risk categories. The odds ratio for muscle invasion were 5.5 (95% confidence interval [CI] 1.3-24.0; p = 0.023) for intermediate risk versus low risk, and 12.7 (95% CI 3.0-54.5; p = 0.0006) for high risk versus low risk. Limitations include the retrospective design and selection bias (all patients underwent RNU). Patients with low-risk UTUC represent ideal candidates for KSS, while some patients with intermediate-risk UTUC may also be considered. This classification needs further prospective validation and may help stratification in clinical trial design. We investigated factors predicting stage 2 or greater cancer of the upper urinary tract at the time of surgery for ureter and kidney removal and designed a new risk stratification. Patients with low or intermediate risk may be eligible for kidney-sparing surgery with close follow-up. Our classification scheme needs further validation based on cancer outcomes.

Sections du résumé

BACKGROUND
The European Association of Urology risk stratification dichotomizes patients with upper tract urothelial carcinoma (UTUC) into two risk categories.
OBJECTIVE
To evaluate the predictive value of a new classification to better risk stratify patients eligible for kidney-sparing surgery (KSS).
DESIGN, SETTING, AND PARTICIPANTS
This was a retrospective study including 1214 patients from 21 centers who underwent ureterorenoscopy (URS) with biopsy followed by radical nephroureterectomy (RNU) for nonmetastatic UTUC between 2000 and 2017.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS
A multivariate logistic regression analysis identified predictors of muscle invasion (≥pT2) at RNU. The Youden index was used to identify cutoff points.
RESULTS AND LIMITATIONS
A total of 811 patients (67%) were male and the median age was 71 yr (interquartile range 63-77). The presence of non-organ-confined disease on preoperative imaging (p < 0.0001), sessile tumor (p < 0.0001), hydronephrosis (p = 0.0003), high-grade cytology (p = 0.0043), or biopsy (p = 0.0174) and higher age at diagnosis (p = 0.029) were independently associated with ≥pT2 at RNU. Tumor size was significantly associated with ≥pT2 disease only in univariate analysis with a cutoff of 2 cm. Tumor size and all significant categorical variables defined the high-risk category. Tumor multifocality and a history of radical cystectomy help to dichotomize between low-risk and intermediate-risk categories. The odds ratio for muscle invasion were 5.5 (95% confidence interval [CI] 1.3-24.0; p = 0.023) for intermediate risk versus low risk, and 12.7 (95% CI 3.0-54.5; p = 0.0006) for high risk versus low risk. Limitations include the retrospective design and selection bias (all patients underwent RNU).
CONCLUSIONS
Patients with low-risk UTUC represent ideal candidates for KSS, while some patients with intermediate-risk UTUC may also be considered. This classification needs further prospective validation and may help stratification in clinical trial design.
PATIENT SUMMARY
We investigated factors predicting stage 2 or greater cancer of the upper urinary tract at the time of surgery for ureter and kidney removal and designed a new risk stratification. Patients with low or intermediate risk may be eligible for kidney-sparing surgery with close follow-up. Our classification scheme needs further validation based on cancer outcomes.

Identifiants

pubmed: 33773965
pii: S2405-4569(21)00097-3
doi: 10.1016/j.euf.2021.03.018
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

491-497

Informations de copyright

Copyright © 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Gautier Marcq (G)

Department of Surgery, Division of Urology, McGill University Health Center, Montreal, Canada; Urology Department, Claude Huriez Hospital, CHU Lille, Lille, France.

Beat Foerster (B)

Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland.

Mohammad Abufaraj (M)

Department of Urology, Medical University of Vienna, Vienna, Austria; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan.

Surena F Matin (SF)

Department of Urology, MD Anderson Cancer Center, Houston, TX, USA.

Mounsif Azizi (M)

Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA; Department of Surgery, Division of Urology, Hôpital du Sacré-Coeur de Montréal, University of Montreal, Montreal, Canada.

Mohit Gupta (M)

Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Wei-Ming Li (WM)

Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Department of Urology, School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.

Thomas Seisen (T)

Urology, GRC 5, Predictive ONCO-URO, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne University, Paris, France.

Timothy Clinton (T)

Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Evanguelos Xylinas (E)

Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Paris Descartes University, Paris, France.

M Carmen Mir (MC)

Instituto Valenciano de Oncologia Foundation, Valencia, Spain.

Donald Schweitzer (D)

Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

Andrea Mari (A)

Department of Urology, Careggi Hospital, University of Florence, Florence, Italy.

Shoji Kimura (S)

Department of Urology, Jikei University School of Medicine, Tokyo, Japan.

Marco Bandini (M)

Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.

Romain Mathieu (R)

Department of Urology, University of Rennes, Rennes, France.

Ja H Ku (JH)

Department of Urology, Seoul National University Hospital, Seoul, Korea.

Georgi Guruli (G)

Division of Urology, Virginia Commonwealth University, Richmond, VA, USA.

Markus Grabbert (M)

Department of Urology, Uro-Oncology, University Hospital Cologne, Cologne, Germany.

Anna K Czech (AK)

Department of Urology, Jagiellonian University Medical College, Krakow, Poland.

Tim Muilwijk (T)

Department of Urology, University Hospitals Leuven, Leuven, Belgium.

Armin Pycha (A)

Department of Urology, Provincial Hospital of Bozen, Bozen, Italy; Medical School, Sigmund Freud University, Vienna, Austria.

David D'Andrea (D)

Department of Urology, Medical University of Vienna, Vienna, Austria.

Firas G Petros (FG)

Department of Urology, MD Anderson Cancer Center, Houston, TX, USA; Department of Urology and Kidney Transplant, The University of Toledo Medical Center and Eleanor N. Dana Cancer Center, Toledo, OH, USA.

Philippe E Spiess (PE)

Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA.

Trinity Bivalacqua (T)

Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Wen-Jeng Wu (WJ)

Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Department of Urology, School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.

Morgan Rouprêt (M)

Urology, GRC 5, Predictive ONCO-URO, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne University, Paris, France.

Laura-Maria Krabbe (LM)

Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology, University Hospital Muenster, Muenster, Germany.

Kees Hendricksen (K)

Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

Shin Egawa (S)

Department of Urology, Jikei University School of Medicine, Tokyo, Japan.

Alberto Briganti (A)

Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.

Marco Moschini (M)

Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy; Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.

Vivien Graffeille (V)

Department of Urology, University of Rennes, Rennes, France.

Riccardo Autorino (R)

Division of Urology, Virginia Commonwealth University, Richmond, VA, USA.

Patricia John (P)

Department of Urology, Uro-Oncology, University Hospital Cologne, Cologne, Germany.

Axel Heidenreich (A)

Department of Urology, Uro-Oncology, University Hospital Cologne, Cologne, Germany.

Piotr Chlosta (P)

Department of Urology, Jagiellonian University Medical College, Krakow, Poland.

Steven Joniau (S)

Department of Urology, University Hospitals Leuven, Leuven, Belgium.

Francesco Soria (F)

Department of Urology, Medical University of Vienna, Vienna, Austria; Division of Urology, Department of Surgical Sciences, University of Torino School of Medicine, Turin, Italy.

Phillip M Pierorazio (PM)

Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Shahrokh F Shariat (SF)

Department of Urology, Medical University of Vienna, Vienna, Austria; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.

Wassim Kassouf (W)

Department of Surgery, Division of Urology, McGill University Health Center, Montreal, Canada. Electronic address: wassim.kassouf@muhc.mcgill.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH